Stockwinners Market Radar for September 23, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:39 EDT Tetra Tech acquires RPS Group for 222 pence per share - Tetra Tech is pleased to announce that it has reached an agreement with RPS Group on the terms of an all-cash acquisition of RPS Group for 222 pence per share. The Acquisition has been unanimously recommended by the Board of Directors of RPS Group. The RPS Group employs 5,000 associates in Europe, the United Kingdom, Asia Pacific, and North America, delivering high-end solutions especially in energy transformation, water, and program management for government and commercial clients. It is intended that the Acquisition will be implemented by means of a Court-sanctioned scheme of arrangement under Part 26 of the U.K. Companies Act 2006. The purpose of the Scheme is to provide for Tetra Tech to indirectly become the owner of the entire issued and to be issued share capital of RPS Group. Subject, amongst other things, to the satisfaction or waiver of the conditions, the approval of the Scheme by the RPS Group shareholders, the receipt of applicable regulatory approvals and the Court's sanction of the scheme of arrangement, it is expected that the Acquisition will complete by the end of 2022. The Acquisition is expected to be mid to high teen percent accretive to adjusted earnings per share after realizing the full benefit from an expected GBP21M in cost synergies and integration into Tetra Tech. The cost to realize these synergies is estimated to be GBP16M and would be substantially incurred in first twelve months after closing. Adjusted EPS excludes one-time transaction related costs and intangible amortization.

18:20 EDT Cavco Industries announces acceptance of settlement in SEC action - Cavco Industries announced that the United States District Court for the District of Arizona approved the settlement of the SEC action against the company. The action was based on securities trading in 2017 directed by Joseph Stegmayer, former chief executive officer, which resulted in an unrealized gain of approximately $265,000 for the company. Without admitting or denying the findings of the consent judgment, the company agreed to the imposition of an injunction against future violations of the antifraud and internal accounting control provisions of the Securities Exchange Act of 1934 and a monetary penalty of $1.5M. The settlement resolves all claims in the action against the company. Daniel Urness, its former CFO, is the only remaining defendant in the ongoing action. Stegmayer settled the SEC claims against him last year. "After working to resolve this matter for an extended period of time, we are very happy to have reached a settlement on reasonable terms," said President and CEO Bill Boor.

17:29 EDT Xperi to replace SelectQuote in S&P 600 at open on 10/3 - Xperi (XPER) will be added to the S&P SmallCap 600 prior to the open of trading on Monday, October 3 replacing SelectQuote (SLQT), which will be removed from the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, October 4. Xperi Holdings is spinning off Xperi (new) in a transaction expected to be completed October 3, pending final conditions. Post spin-off, parent company Xperi Holdings will remain in the S&P SmallCap 600. It will change its name and ticker symbol to Adeia (ADEA).

17:24 EDT Leslie's to replace GCP Applied Technologies in S&P 600 at open on 9/28 - Compagnie de Saint-Gobian S.A. is acquiring GCP Applied Technologies in a transaction expected to be completed on or about that date, pending final conditions.

17:22 EDT ExlService to replace EQT Corporation in S&P 400 at open on 10/3

17:19 EDT PG&E to replace Citrix in S&P 500 at open on 10/3 - Vista Equity Partners is acquiring Citrix Systems in a transaction expected to be completed September 30, pending final conditions.

17:09 EDT Raytheon Technologies awarded $769.87M Navy contract modification - Raytheon Technologies was awarded a $769.87M firm-fixed-price, cost-plus-fixed-fee modification to a previously awarded, indefinite-delivery/indefinite-quantity contract. This modification increases the contract ceiling to procure propulsion system spare parts, modules, support equipment/packaging handling shipping and transportation material, and depot lay-in material in support of the F-135 propulsion system requirements for the Air Force, Marine Corps, Navy, Foreign Military Sales customers and non-Department of Defense participants. Work is expected to be completed in December 2025. No funds will be obligated at the time of award; funds will be obligated on individual orders as they are issued. The Naval Air Systems Command is the contracting activity.

17:03 EDT XPeng announces adjustments to configurations of G9 SUV - XPeng announced adjustments to the configurations of its G9 Flagship SUV, launched in the Chinese market on September 21. These adjustments reflect the optional spec packages of technologies. All XPeng G9 versions come standard with 800 V high-voltage platform and 3C battery pack. The 650 versions provide optional equipment for 4C supercharging battery pack.

16:22 EDT Brookfield board approves distribution of 25% interest in asset mgt. business - Brookfield announced that its Board of Directors has unanimously approved the transaction for the public listing and distribution of a 25% interest in its asset management business, through Brookfield Asset Management. Pursuant to this approval, Brookfield has entered into an arrangement agreement in connection with the implementation of the transaction. The transaction will result in the division of Brookfield into two publicly traded companies - the Corporation and the Manager - with the holders of Brookfield's class A limited voting shares, class B limited voting shares and Series 8 and 9 class A preference shares becoming shareholders of the Manager on completion. The transaction will enable Shareholders to access a leading pure-play global alternative asset management business, through the Manager. Brookfield Corporation will continue focusing on deploying capital across its operating businesses, growing its cash flows and compounding that capital over the long term. A special meeting of Shareholders has been called for November 9, 2022 and Shareholders of record as of the close of business on October 3, 2022 will be entitled to vote at the Meeting. The Board of Directors of Brookfield unanimously recommends that Shareholders vote in favor of the resolution approving the Arrangement, as well as the related matters to be approved at the Meeting.

16:21 EDT Bluebird Bio names Katherine Breedis interim CFO - In a regulatory filing, on September 22, 2022, the board of directors of Bluebird Bio appointed Katherine Breedis to serve as the company's interim Chief Financial Officer and designated Ms. Breedis as the company's principal financial officer and principal accounting officer, succeeding Jason F. Cole, the company's current Chief Strategy and Financial Officer. Breedis' appointment will be effective upon Cole's departure from the company on October 14, 2022. Breedis has served as a Chief Financial Officer Consultant at Danforth Advisors, strategic finance and operations firm with a focus on life sciences companies, since July 2021, where she provides interim chief financial officer and strategic business development consulting services to public and private U.S.-based and international biotechnology companies.

16:09 EDT Twin Disc signs lease agreement for office location in Milwaukee - Twin Disc announced the lease of an office space in Milwaukee, WI. The 8,100 square foot space on the fourth floor of an office building located on Erie Street in Milwaukee's Historic Third Ward will accommodate approximately 25 employees. The company expects to relocate its corporate team to the new location in early 2023. The lease of an office space in Milwaukee, and tentative sale of its location at 1328 Racine Street, is part of Twin Disc's asset optimization strategy. "We continue to find ways to reduce our footprint and provide more value for our shareholders, customers and employees," said John Batten, President & Chief Executive Officer, Twin Disc, Inc. "We assessed several locations for the new office space and found that downtown Milwaukee better suits this subset of employees."

14:34 EDT GSUN Stock trading resumes

14:18 EDT Tellurian says updated Driftwood LNG financing strategy, seeks equity partners - Tellurian announced that it has updated its Driftwood LNG financing strategy to prioritize securing equity partners. "Part of this strategy includes introducing flexibility in its liquefied natural gas portfolio with the termination of two current sales and purchase agreements," the company stated. Tellurian President and CEO Octavio Simoes said, "The potential corporate and strategic partners we are seeking may want liquefied natural gas volumes that they can sell globally and now we have some capacity to offer that option. We have made good progress on our construction plan and will continue funding that with our cash and operating cash flow. What has not changed for Tellurian is that we are an operating natural gas producer with revenue from our gas sales. Last quarter we produced nine billion cubic feet of natural gas and had over $61 million in sales, and since then we have closed the EnSight acquisition. Currently we have 11 natural gas wells in various stages of completion and therefore expect a significant increase in production and sales next quarter. In addition, we will add to our value when our fully permitted Driftwood LNG project is completed, and we can reach the global markets with LNG sales at global prices."

14:07 EDT Global Cord Blood trading halted by NYSE for 'regulatory concern' - Shares of Global Cord Blood were halted by the NYSE at 2:01:12 pm ET, citing "regulatory concern" as the reason, according to a post to the exchange's site. The halted followed Blue Ocean Structure Investment Company, which identifies itself as "a significant shareholder" of Global Cord Blood, having announced the Grand Court of the Cayman Islands issued an order granting the appointment of joint provisional liquidators for Global Cord. "The powers of the company's Board of Directors have been suspended. The JPLs may restore any powers of the directors of the company in writing as the JPLs in their absolute discretion shall see fit having determined that the exercise of such power is necessary to give effect to the order," according to a press release issued by Blue Ocean.

13:02 EDT Baker Hughes reports U.S. rig count up 1 to 764 rigs - Baker Hughes reports that the U.S. rig count is up 1 from last week to 764 with oil rigs up 3 to 602, gas rigs down 2 to 160 and miscellaneous rigs unchanged at 2. The U.S. Rig Count is up 243 rigs from last year's count of 521 with oil rigs up 181, gas rigs up 61 and miscellaneous up 1. The U.S. Offshore Rig Count is up 1 to 16, up 6 year-over-year. The Canada Rig Count is up 4 from last week to 215, with oil rigs up 2 to 146, gas rigs up 2 to 67. The Canada Rig Count is up 53 rigs from last year's count of 162, with oil rigs up 52, gas rigs up 2 and miscellaneous down 1.

12:40 EDT Goldman Sachs announces preliminary court approval of 1MBD derivative settlement - The Goldman Sachs Group announced that on September 16, 2022, the U.S. District Court for the Southern District of New York preliminarily approved a settlement agreement resolving a shareholder derivative lawsuit involving the firm. In accordance with the Court's order preliminarily approving the settlement, Goldman Sachs is making disclosure of the settlement to its shareholders in the Notice of Settlement of Shareholder Derivative Litigation and Hearing.

12:07 EDT Permianville Royalty Trust falls -13.7% - Permianville Royalty Trust is down -13.7%, or -51c to $3.22.

12:03 EDT Artivion falls -29.0% - Artivion is down -29.0%, or -$5.36 to $13.14.

12:00 EDT Vertical Aerospace rises 15.0% - Vertical Aerospace is up 15.0%, or 94c to $7.21.

11:17 EDT Magnetar reports 6.02% stake in ChannelAdvisor - Magnetar Financial disclosed a 6.02% stake in ChannelAdvisor, which represents over 1.73M shares. The filing allows for activism. Magnetar said it acquired the shares after the public announcement of ChannelAdvisor's merger agreement "for purposes of receiving the merger consideration described below upon consummation of the Merger." CommerceHub agreed to acquire the outstanding shares of ChannelAdvisor for $23.10 per share in cash.

11:04 EDT Netflix announces resignation of Principal Accounting Officer Ken Barker - Netflix disclosed that on September 22, Ken Barker, its Principal Accounting Officer, submitted his resignation, effective October 7. Barker's resignation "was a personal decision and is not the result of any disagreement with the Company on any matter relating to the Company's financials, operations, policies, or practices," Netflix said in a regulatory filing. Effective immediately following Barker's resignation, Spencer Neumann, the company's Chief Financial Officer, will assume the role of Principal Accounting Officer while Netflix searches for a permanent replacement.

11:02 EDT Tellurian down 22% after Shell notice of termination - Shares of Tellurian (TELL), which have resumed trading after disclosing that the company received a notice of termination from Shell NA LNG (SHEL) with respect to the LNG sale and purchase agreements 1 and 2 between Driftwood LNG LLC and Shell, are down 62c, or 22%, to $2.15.

10:43 EDT Stabilis Solutions Inc trading resumes

10:38 EDT Stabilis Solutions Inc trading halted, volatility trading pause

10:04 EDT Fuwei Films trading halted, volatility trading pause

10:02 EDT NexTier Oilfield falls -11.2% - NexTier Oilfield is down -11.2%, or -89c to $7.09.

10:01 EDT Artivion falls -22.2% - Artivion is down -22.2%, or -$4.10 to $14.40.

10:00 EDT ProShares UltraShort Bloomberg Natural Gas rises 10.7% - ProShares UltraShort Bloomberg Natural Gas is up 10.7%, or $1.60 to $16.61.

09:52 EDT NexTier Oilfield falls -9.7% - NexTier Oilfield is down -9.7%, or -77c to $7.21.

09:52 EDT Artivion falls -20.0% - Artivion is down -20.0%, or -$3.70 to $14.80.

09:51 EDT EBET signs sportsbook and exclusive casino wagering pact with Metagames - EBET announced that it has entered into a sportsbook and exclusive casino wagering media marketing agreement with Metagames Marketing Inc., providing access to one of the largest Spanish-speaking digital and TV networks worldwide. Under the agreement, Metagames will provide media placements via its affiliates in exchange for a share of sportsbook and casino games net gaming revenue. The campaign will provide access to up to 45 national TV networks, 68 radio stations and 65 movie theaters in Latin American countries including: Peru, Ecuador, Bolivia, Chile, Paraguay, Guatemala, Costa Rica, Nicaragua, El Salvador, Honduras and the Dominican Republic. The media campaign will include traditional TV and radio spots in combination with integrated brand placement and contests within daytime programming and reality TV shows. EBET's brand Karamba will be featured in leading shows such as "Combate," "Sabadisimo," and "Magaly TV," with full segments and interactive games. Adding to the fan base reach of each show, full online video and banner campaigns will be run on each show's social channels, as well as the networks' streaming channels.

09:49 EDT HHG Capital Corp trading resumes

09:48 EDT Scor ADR rises 8.8% - Scor ADR is up 8.8%, or $2.39 to $29.65.

09:47 EDT Silver Crest Acquisition Corp trading halted, volatility trading pause

09:44 EDT HHG Capital Corp trading halted, volatility trading pause

09:35 EDT Avenue Therapeutics trading resumes

09:19 EDT Live Current Media appoints Alexander Mecl as CMO - Live Current Media announced that Alexander Mecl has joined the company as Chief Marketing Officer. As Live Current's CMO, Mr. Mecl will be responsible for the company's overall marketing strategy and execution, building out the marketing and creative team to keep pace with the company's rapid-growth trajectory. Prior to joining Live Current, Mr. Mecl was the senior managing director and executive producer for Bruce Brown Films.

09:16 EDT Solicitor general recommends Supreme Court shouldn't review Amgen patent case - The U.S. solicitor general recommended that the Supreme Court not hear a case in which Amgen argued that a federal appeals court incorrectly determined its patent claims on a cholesterol medication are invalid. The solicitor general's office maintained the appeals court was correct and that Amgen's patent claims are invalid, because "undue experimentation" would be required to "enable their full scope," adding that "the court of appeals' enablement determination was reasonable on the record before it" and Amgen's challenge "does not warrant further review." Reference Link

09:07 EDT BYND Cannasoft closes acquisition of Zigi Carmel Investments valued at $28M - BYND Cannasoft Enterprises announced that, further to its news release of September 19, 2022, it has completed the purchase of all of the issued and outstanding shares of Zigi Carmel Initiatives & Investments from Carmel Zigdon. Under the terms of the share purchase agreement, the Company issued 7,920,000 common shares to the vendor. These shares are subject to a hold period and may not be traded in Canada before January 23, 2023. The Company also reports that Carmel has been appointed as a director of BYND. Carmel invented the concept for the EZ-G device back in 2021 and since then has developed it for commercialization. He currently manages the online shopping site ZCRAIV, an online clothes store generating revenues in the millions of US$ per year. Carmel Zigdon has acquired beneficial ownership and control over 7,920,000 common shares of the Company at a deemed price per share of $4.735 for a total deemed price of $37,501,200. The Shares were acquired on September 22, 2022 pursuant to the Company's purchase of ZC. Immediately following the Acquisition, the Acquiror owned a total of 7,920,000 Shares representing 20.99% of the Company's 37,736,810 issued and outstanding Shares.

09:04 EDT Capital Power, Manulife Investment Management complete facility acquisition - Capital Power and Manulife Investment Management, on behalf of the Manulife Infrastructure Fund II and its affiliates, announced today that they have completed the acquisition of a 100% interest in MCV Holding Company, which owns Midland Cogeneration Venture, a 1,633-megawatt natural gas combined-cycle cogeneration facility. The acquisition was previously announced on July 12, 2022. Midland Cogen was acquired from OMERS Infrastructure Management Inc. and its co-investors for $894M, subject to working capital and other closing adjustments, and includes the assumption of $521M of project level debt. Under the 50/50 joint venture with Manulife Investment Management, Capital Power and its joint venture partner each contributed approximately $186M. Capital Power financed the transaction using cash on hand and its credit facilities. Capital Power will be responsible for operations and maintenance and asset management for which it will receive an annual management fee. Located in Michigan, Midland Cogen is the largest gas-fired cogeneration facility in North America, is a critical asset to support grid reliability during the transition to renewables and is well-positioned, given anticipated market conditions, for recontracting beyond 2030. It currently operates under long-term contracts until 2030 and 2035 with high quality counterparties. For Capital Power, the acquisition provides immediate adjusted funds from operations accretion with the 5-year average accretion forecasted to be $0.30 per share, representing a 7.0% increase. Financial projections include an average adjusted EBITDA of $59M per year and an average AFFO of $35M per year during the 5-year period from 2023 to 2027.

09:01 EDT Evofem announces issuance of U.S. patent covering Phexxi COM - Evofem Biosciences announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,439,610, which covers the composition of matter of Phexxi. "We are extremely pleased with the continued development of the Phexxi patent portfolio, which comprises more than 40 patents. This newly issued patent expands the breadth and depth of our Phexxi intellectual property portfolio, adding composition of matter protection to our Orange Book-listed method of use patents and the further protection afforded by the QIDP designation granted by the FDA for the prevention of chlamydia and gonorrhea in women," said Saundra Pelletier, Chief Executive Officer of Evofem. Top-line data from EVOGUARD, Evofem's registrational Phase 3 clinical trial evaluating Phexxi for these two potential new indications, are expected in mid-October. Preliminary CDC data for 2021 show that infections with chlamydia and gonorrhea continued to increase during the second year of the COVID-19 pandemic, with no signs of slowing.

08:37 EDT iHeartMedia, Neustar announce new marketing partnership - Neustar, a TransUnion (TRU) company, announced a new partnership with iHeartMedia (IHRT), to include broadcast radio in end-to-end marketing attribution. The solution expands the Neustar Unified Measurement Solution, which spans Marketing Mix Modeling, or MMM, and Marketing Attribution solution to include the iHeart broadcast radio universe. Neustar is the first attribution service to unify the measurement of radio, which reaches over 90% of Americans a month, with all other channels into one platform. This innovation provides critical insights into the incremental contribution the massive reach of broadcast radio has on consumer purchase behavior.

08:34 EDT ABVC BioPharma provides ADHD Phase II Part 2 clinical update - ABVC Biopharma announced enrollment progress in the Phase II Part 2 clinical study of the Company's ADHD medicine, ABV-1505, currently being conducted at five prestigious medical centers in Taiwan. The Part 2 study is a randomized, double-blind, placebo-controlled study, titled "A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients with Attention-Deficit Hyperactivity Disorder, Part 2" and is expected to eventually enroll approximately 100 patients in Taiwan and the United States. Since results of the first subject treated in Taiwan were reported on May 10, 2022, 30 subjects have now been enrolled in the study from a total of 43 subjects screened. Eighteen of the enrolled participants have already completed the 8-week treatment in accordance with the study design. In addition, the company has been notified that the University of California, San Francisco Medical Center Institutional Review Board has approved participation in the Part 2 study, set to begin in the fourth quarter of this year. Part 1 of the Phase II study of ABV-1505 was conducted at UCSF from January 2020 through July 2020 and was accepted by the US Food & Drug Administration in October of 2020. "We are pleased to see 30 subjects have been enrolled in the Phase II Part 2 ADHD clinical trial, and 18 participants have completed the 8-week treatment," said Dr. Howard Doong, Chief Executive Officer of ABVC BioPharma. "We are also delighted that the University of California, San Francisco is involved in the Phase II Part 2 study. With UCSF participation, in addition to the five Taiwan sites, we anticipate that enrollment for the study will accelerate substantially, and worldwide we are expecting to complete the Part 2 study in the third quarter of 2023."

08:33 EDT NanoVibronix announces UroShield approved for sale by NHS - NanoVibronix announced its UroShield has been approved for sale by the U.K.'s National Health System's, or NHS, internal supply organization, NHS Supply Chain, through a new contract.

08:32 EDT Corphousing acquires rights to The Tuscany Hotel in New York City - CorpHousing announced it has acquired long-term rights to The Tuscany Hotel in New York City via a 15-year Master Lease Agreement, or MLA. The addition of The Tuscany brings to nine the total number of hotels in CHG's portfolio and the 124 units added under this MLA increases CHG's total units under long-term lease to 977. CorpHousing plans to start operating The Tuscany during Q4 and will market the property under its LuxUrban brand.

08:31 EDT Tellenger awarded three-year contract by national security agency - Tellenger announced that they have been awarded a three-year contract by a National Security Agency. The contract includes a base year, commencing in October 2022, with two option years for document and system development work.

08:21 EDT Pono Capital Two announces separate trading of Class A stock, warrants - Pono Capital Two announced that holders of the units sold in the Company's initial public offering of 11,500,000 units completed on August 9, 2022, may elect to separately trade the shares of Class A common stock and warrants included in the units commencing on or about September 26, 2022. Holders of units will need to have their broker contact Continental Stock Transfer & Trust Company, the Company's transfer agent, in order to separate the units into shares of Class A common stock and warrants. Those units not separated will continue to trade on the Nasdaq Global Market under the ticker symbol "PTWOU," and the Class A common stock and warrants that are separated will trade on Nasdaq under the symbols "PTWO" and "PTWOW," respectively.

08:10 EDT Bigg Digital Assets' TerraZero signs LOI for public listing on TSX-V - BIGG Digital Assets announced that its portfolio company TerraZero Technologies has signed a letter of intent with Whatcom Capital II Corp. which would result in TerraZero becoming publicly traded via a reverse take-over transaction.

08:08 EDT Immutep receives EUR 1,804,341 R&D tax incentive from French government - Immutep announces it has received a EUR 1,804,341 research and development, R&D, tax incentive payment in cash from the French Government under its Credit d'Impot Recherche scheme, CIR. The "Credit d'Impot Recherche", meaning "Research Tax Credit", is a French government tax incentive by which French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure.

08:06 EDT Zivo Bioscience CEO issues letter to shareholders - Zivo Bioscience issued the following letter to shareholders from its chairman, president and CEO, John Payne. "Having served as a member of the Board of Directors of ZIVO Bioscience since 2013 and as Chairman since 2019, I've been integrally involved in setting ZIVO's strategy and evaluating the potential of a range of valuable products derived from our proprietary algal culture. Now serving as President and CEO, I'm focusing our Company to deliver commercial results quickly and in areas of highest value. Through establishing partnerships and scaling our manufacturing capacity, ZIVO is undergoing a transformation aimed at maximizing the value of our product portfolio for our customers, partners, and shareholders. Since I assumed day-to-day leadership at the start of this year, my colleagues and I have left no stone unturned in reviewing all avenues to best reshape ZIVO to maximize the value of our products and our intellectual property. We have worked diligently to build the necessary infrastructure, and I believe that 2023 will showcase the results of our efforts. I'm proud to share that our redeveloped strategy is materializing nicely and that we are in a stronger position than ever before to achieve meaningful revenue and recognition for the value of our assets. Our strategy remains two-pronged and is focused on driving significant value inflection through targeted development of our biotech business and delivering near-term revenue through our agtech business. Regardless of the end market, we will maximize value through partnerships and by commercializing the unique capabilities of products derived from our proprietary algal culture. Through this letter I'd like to provide an overview of why others find our product candidates to be so attractive. I will then share my vision for ZIVO to maximize commercial potential, our long-term strategy to achieve that vision, the steps we are taking now, and the near-term goals our shareholders can look forward to us achieving..."

08:05 EDT Equifax, Experian and TransUnion to continue to offer free weekly credit reports - The three nationwide credit reporting agencies - Equifax (EFX), Experian (EXPGY) and TransUnion (TRU) - are taking joint action to continue offering free weekly credit reports to consumers in the United States through the end of 2023. This benefit will help consumers manage their financial health during a period of rising inflation and unprecedented economic uncertainty coming out of the COVID-19 pandemic.

08:03 EDT Rhythm publishes children's book in collaboration with BBS Foundation - Rhythm Pharmaceuticals announced the publication of a children's book developed in collaboration with the Bardet-Biedl Syndrome Foundation. The publication announcement of the book, titled, "Understanding Hunger & Bardet-Biedl Syndrome: Gabe's Story," comes ahead of the second annual BBS Global Day on September 24. "Gabe's Story" is designed to help children living with BBS make sense of their feelings, provide education on why they are experiencing insatiable hunger, and recognize they are not alone.

08:02 EDT Bionano Genomics announces launch of CLIA-certified Bionano Laboratories - Bionano Genomics announced the launch of Bionano Laboratories, a new organization that combines Bionano's optical genome mapping, OGM, data services with the clinical testing services previously offered by Lineagen, and the launch of Bionano Laboratories' first OGM-based laboratory developed test, LDT. Bionano Laboratories recently received CLIA-certification for its lab in San Diego. This certification will enable Bionano Laboratories to offer services to customers seeking to implement OGM into their diagnostic routines and for research applications with hospitals, pharmaceutical companies, and other parties that may desire a more robust regulatory structure for their projects. Erik Holmlin, PhD, president and chief executive officer of Bionano Genomics added, "We want to congratulate Alka along with her outstanding team for all the work they've done. The development of LDTs will allow Bionano Laboratories to introduce OGM-based assays to interested physicians and to seek reimbursement from insurance companies for these testing services. We believe our ability to offer CLIA-certified services will enable us to execute our growth strategy and to fulfill our vision of changing the way the world sees the genome."

07:54 EDT Glencore to acquire Newmont's 18.75% shareholding in the MARA project - Glencore International (GLNCY) announced, and has made Yamana Gold Inc. (AUY) aware under the terms of the MARA joint venture, that it has reached an agreement to acquire Newmont Corporation's (NEM) 18.75% shareholding in the MARA Project. Following completion of the Agreement, Yamana remains the MARA JV operator with a 56.25% interest in MARA, with Glencore owning the remaining 43.75%. Yamana welcomes Glencore's increased stake in the Project and believes the Agreement is a positive step for MARA, as the consolidation of ownership amongst partners provides a further endorsement of the quality and strategic optionality inherent in the Project, as well as underpinning its value. Under the terms of the Agreement, Glencore will pay Newmont $124.9M upon closing and a $30M deferred payment upon commercial production subject to an annual interest charge of 6%. Total deferred consideration is capped at $50M. Based on the NPV of $1.9B as determined by the 2020 PFS-B results, the implied P/NAV transaction multiple is approximately 0.5x which Yamana believes is in line with comparable precedent transactions for the sale of a minority interest in projects at similar stage of development. Glencore previously operated Minera Alumbrera, in which Yamana was a partner. Currently Minera Alumbrera is part of the MARA Project after its integration with Minera Agua Rica, which Yamana wholly owned. Glencore has worked with Yamana in the formation of the MARA JV, the integration of the processing plant, related infrastructure and other assets of Minera Alumbrera with the Agua Rica deposit, and the advancement of the Project since then. Yamana looks forward to continuing its work with Glencore and the local stakeholders as MARA advances its permitting, engineering, social licensing and field work towards the goal of finalizing the feasibility study and the environmental and social impact assessment, which the Company expects will further increase the Project's value.

07:42 EDT Glencore to acquire Newmont 18.75% shareholding in MARA Project for $124.9M - Glencore (GLNCY) and Newmont (NEM) announced they have reached an agreement in which Glencore will acquire Newmont's 18.75% shareholding in the MARA Project. Following completion of the transaction, Glencore will own 43.75% of MARA. Under the terms of the agreement, Glencore will pay $124.9M upon closing and a $30M deferred payment upon commercial production subject to an annual interest charge of 6%. Total deferred consideration is capped at $50M. The closing of the transaction is subject to customary conditions and regulatory filings. The MARA Project, located in the Catamarca province of Argentina, is a joint venture formed in December 2020 between Yamana Gold (AUY), Glencore and Newmont following the integration of the Minera Alumbrera plant and mining infrastructure and Agua Rica project. Under the new structure, Yamana Gold Inc. will remain the operator with 56.25% of MARA, with Glencore owning the remaining shares. A core asset for Yamana and Glencore, MARA has proven and probable mineral reserves of 5.4M tons of copper and 7.4M ounces of gold contained in 1.105B tons of ore with an initial mine life of 28 years.

07:31 EDT Daseke appoints Aaron Coley as CFO - Daseke named Aaron Coley as the Company's new Executive Vice President, CFO, effective October 28th of this year. In this role, Mr. Coley will be responsible for managing all treasury, accounting, tax, investor relations, financial planning and analysis, and capital market activities, and will be charged with managing the Company's balance sheet and improving its corporate finance capabilities. Coley brings over 24 years of business experience and 11 years of experience as a CFO, most recently with Pilot Thomas Logistics.

07:11 EDT Guardforce, Riversoft partner to co-develop, launch robotic travel concierge - Guardforce announced that it has entered into a partnership agreement with Riversoft, a Peakwork Company who is specialized in travel management software, to co-develop and co-launch contactless travel services with its existing GFAI's Concierge robots. Guardforce AI and Riversoft plan to co-develop these contactless travel services in a new robotic solution to be known as Robot Travel Agency, RTA. Olivia Wang, Chairwoman and Chief Executive Officer of Guardforce AI, stated, "We are excited about our partnership with Riversoft and our joint plans to launch the RTA. According to the Global Business Travel Association's latest Business Travel Index, global business travel activity will continue to recover in 2023 and is headed towards a full recovery to 2019 pre-pandemic spending levels of USD $1.4 trillion. Our strategic objective of the RTA is to launch in the hospitality industry to help travelers find exclusive local promotions for restaurants, events, and stores. The hotel industry is one of our important and major markets for our robotic solutions and we are working with Riversoft to further expands our services, enabling us to provide more efficient, and convenient experiences to our customers and clients."

07:09 EDT Givaudan, LanzaTech collaborate to develop sustainable fragrance ingredients - Givaudan (GVDNY) and LanzaTech NZ have announced a collaboration for the development of sustainable fragrance ingredients from renewable carbon. The research collaboration with Givaudan is one that is expected to leverage this synthetic biology capability and go beyond the production of ethanol, with the companies working together to establish novel pathways to key fragrance ingredients used across the Givaudan portfolio. By searching for new opportunities to bring perfumery material innovations to life, the companies have a shared goal of using sustainable methods to continue serving consumers through enhancing the perfumery palette and being good for the planet as well. "Givaudan has long been an expert in pairing innovation and technology in the world of fragrance and we are excited to be working with a company that shares our vision of a post pollution future," said Jennifer Holmgren, CEO of LanzaTech. "Together, thanks to the power of synthetic biology, we are expanding the way in which we can deliver sustainable solutions to all consumers, giving them a choice as to where their carbon comes from while protecting our planet." LanzaTech has entered into a merger agreement for a business combination transaction with AMCI Acquisition Corp. II (AMCI).

07:08 EDT Tiziana Life Sciences CMO purchases 75,000 common shares - Tiziana Life Sciences announces that it has been notified that Matthew Davis, its Chief Medical Officer, purchased 75,000 common shares at $0.83 per share, bringing his total holding to 175,000 common shares.

07:06 EDT Stingray Group renews normal course issuer bid - Stingray Group announced that the Toronto Stock Exchange has approved the renewal of its normal course issuer bid, authorizing Stingray to repurchase up to an aggregate 2,868,124 subordinate voting shares and variable subordinate voting shares, representing approximately 10% of the "public float" of Subordinate Shares as at September 13, 2022. The net average daily trading volume for the six-month period preceding September 1, 2022 represents 37,616 Subordinate Shares. In accordance with TSX requirements, Stingray is entitled to purchase, on any trading day, up to a total of 9,404 Subordinate Shares representing 25% of this average daily trading volume. Stingray believes that the purchase of up to 2,868,124 Subordinate Shares under the NCIB is an appropriate use of its funds and a desirable investment for Stingray and, therefore, would be in the best interests of Stingray. By making such repurchases, the number of Subordinate Shares in circulation will be reduced and the proportionate interest of all remaining shareholders in the share capital of Stingray will be increased on a pro rata basis. Stingray may repurchase Subordinate Shares on the open market through the facilities of the TSX as well as through other alternative Canadian trading systems, from time to time, over the course of twelve months commencing September 27, 2022 and ending at the latest on September 26, 2023. The actual number of Subordinate Shares purchased under the NCIB, the timing of purchases and the price at which the Subordinate Shares are bought will depend upon management discretion based on factors such as market conditions. All shares repurchased under the NCIB will be cancelled upon their repurchase. In connection with the NCIB, Stingray has established an automatic securities purchase plan with a designated broker whereby shares may be repurchased at times when such purchases would otherwise be prohibited pursuant to regulatory restrictions or self-imposed blackout periods. Under the automatic securities purchase plan, before entering a self-imposed blackout period, Stingray may, but is not required to, ask the designated broker to make purchases under the NCIB. Such purchases will be made at the discretion of the designated broker, within parameters established by Stingray prior to the blackout periods. Outside the blackout periods, purchases are made at the discretion of Stingray's management. The automatic securities purchase plan constitutes an "automatic plan" for purposes of applicable Canadian securities legislation and has been pre-cleared by the TSX. As of September 13, 2022, Stingray had repurchased a total of 1,409,900 Subordinate Shares through the facilities of the TSX as well as through other alternative Canadian trading systems pursuant to its last NCIB at a weighted average price of $6.7729 per share. As of the close of business on September 13, 2022, there were an aggregate of 51,774,302 Subordinate Shares issued and outstanding of which 28,681,245 Subordinate Shares comprised the "public float".

07:04 EDT Artivion stops PROACT Xa clinical trial - Artivion announced that it has stopped the PROACT Xa clinical trial, a prospective, randomized, trial designed to determine if patients with an On-X mechanical aortic valve can be maintained safely and effectively on apixaban rather than on warfarin. The decision was based on the recommendation of the independent Data and Safety Monitoring Board of the trial due to lack of evidence supporting non-inferiority of apixaban to warfarin for valve thrombosis and thromboembolism. The PROACT Xa trial randomized patients having an On-X aortic valve replacement to receive either warfarin or apixaban as their anticoagulant to prevent blood clots. The trial began enrolling in April 2020. The DSMB found that blood clots, resulting in stroke, occurred more frequently in patients receiving apixaban and that continuing the trial was unlikely to achieve the primary endpoint while possibly exposing patients to increased risk. Physician investigators at the trial's sites are being notified to change patients who are in the apixaban arm of the trial back to warfarin. CEO Pat Mackin said, "We are disappointed to stop the PROACT Xa trial as a successful trial would have significantly benefited patients and significantly increased our addressable market opportunity beginning in 2025. Despite stopping the trial, we are reiterating our 2022 outlook of delivering double-digit top-line growth and we remain committed to delivering the financial expectations we communicated in our March investor meeting: Double digit top-line growth, expanding gross margins, and accelerated adjusted EBITDA growth through 2024. We had committed approximately $10 million in annual funding to this study through 2024 and will now redirect these funds to other development opportunities and to incremental EBITDA and cash flow in 2023 and 2024."

07:02 EDT Casi Pharmaceuticals announces exit of Juventas investment - Casi Pharmaceuticals announced that CASI Biopharmaceuticals Co., Ltd, a subsidiary of CASI Pharmaceuticals, entered into an Equity Transfer Agreement with Shenzhen Jiadao Gongcheng Equity Investment Fund, pursuant to which CASI Wuxi agreed to transfer its equity interest in Juventas Biotechnology Co., Ltd amounting to 12.0098% total Juventas equity to Jiadao Gongcheng for $34.03M. The Equity Transfer Agreement states there will be two even payment installments from Jiadao Gongcheng; one payment to be made after the Equity Transfer Agreement is signed and the second payment to be made after the completion of the equity transaction.

06:49 EDT EU commercial vehicle registrations down 17.4% in July, down 8.0% in August - Commercial vehicle registrations in the European Union fell again in July and August - down 17.4% and 8.0% respectively - marking fourteen consecutive months of decline, reported the European Automobile Manufacturers Association. The sharp drop in van registrations was the key contributor to the overall contraction of the commercial vehicle market as all key EU markets faced losses during the summer months, with the exception of Spain, the group said. Publicly traded truck makers and suppliers include Daimler AG (DDAIF), Paccar (PCAR), CNH Industrial (CNHI), Navistar (NAV), Cummins (CMI) and Allison Transmission (ALSN).

06:08 EDT Snow Lake Resources signs MOU with LG Energy Solution for domestic supply chain - Snow Lake Resources has signed a non-binding Memorandum of Understanding, or MOU, with LG Energy Solution as a next step towards building the domestic supply chain for the North American electric vehicle market. Snow Lake Lithium and LGES will collaborate to explore the opportunity to create one of Canada's first lithium hydroxide processing plants in CentrePort, Winnipeg, Manitoba. Under the terms of the MOU, Snow Lake Lithium will supply LGES with lithium over a 10-year period once production starts in 2025. The MOU and contemplated partnership will be subject to a number of conditions, including the completion of due diligence from both parties.A scoping study, in partnership with Primero, is already underway to identify the technologies, innovations and skills required to deliver a world-class lithium hydroxide plant within the Manitoba Province.

06:01 EDT Ascent Solar announces resignation of CEO Victor Lee - Victor Lee has resigned as the company's CEO. The company has commenced a search for a new CEO and expects to make an announcement about new executive leadership in the near future. Four new directors have been appointed to the company's Board of Directors: Louis Berezovsky, Mike French, Felix T. Mantke, and Forest Reynolds. These directors will serve as part of the new leadership team that will help guide the company in its efforts to develop long-term revenue and business opportunities, as Ascent continues its transition as a newly listed company on Nasdaq. As part of the board transition, four previous directors (Amit Kumar, Kim J. Huntley, Will A. Clarke and Victor Lee) agreed to resign from the board. David Peterson continues as a member of the board and has been appointed board chair.

05:21 EDT Innate Pharma announces lacutamab demonstrated clinical responses - Innate Pharma announced that lacutamab, an anti-KIR3DL2 antibody, demonstrated clinical responses in patients with mycosis fungoides, or MF, in the ongoing Phase 2 TELLOMAK clinical trial. The results will be shared in an oral presentation at the EORTC CLTG1 Annual Meeting, taking place from 22-24 September in Madrid, Spain. As of the March 4, data cutoff, patients in the KIR3DL2-expressing MF patients received a median of 4 prior systemic therapies, and had a median follow-up of 12.2 months. In the KIR3DL2 non-expressing cohort, patients received a median of 4.5 prior systemic therapies and had a median follow-up of 13.8 months. Results showed that lacutamab produced a global objective response rate of 28.6% in the KIR3DL2-expressing MF patients, including 2 complete responses and 4 partial responses. Results from the KIR3DL2 non-expressing cohort 3 are also presented. In line with previous observations, lacutamab demonstrated a favorable safety profile in MF also in the skin. Grade = 3 Treatment-related Treatment-Emergent Adverse events were observed in 2/39 patients and 1/39 patients discontinued study drug due to adverse events. Most common TR TEAEs were asthenia, arthralgia and nausea.

05:08 EDT ClearPoint Neuro announces FDA clearance for Prism Neuro Laser Therapy System - ClearPoint Neuro announced its Swedish partner, Clinical Laserthermia Systems, has received 510(k) clearance for its laser which the company plans to commercialize as the ClearPoint Prism Neuro Laser Therapy System.